Precision Bio Q1 sales beat, helped by milestone revenue

Precision Biosciences

05/05/2026 12:36

Overview

US gene editing firm's Q1 revenue rose sharply, beating analyst expectations

Net loss for Q1 narrowed year-over-year

Company ended Q1 with $125.8 mln in cash, expects runway through 2028

Outlook

Company expects existing cash to fund PBGENE-HBV and PBGENE-DMD data milestones through 2028

Result Drivers

MILESTONE REVENUE - Q1 revenue increase driven by milestone revenue recognized under license agreement with TG Therapeutics and a legacy ARCUS agriculture collaboration

LOWER OPERATING EXPENSES - Decrease in general and administrative expenses due to operational discipline and lower employee-related costs

NON-CASH EXPENSES - Higher other expense due to fair value adjustments, including loss on change in fair value of warrant liability and lower interest income

Company press release: ID:nBw9MwDpva

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$10.84 mln
$4.05 mln (4 Analysts)
Q1 EPS
-$0.75
Q1 Net Income
-$18.44 mln
Q1 Income from Operations
-$9.08 mln
Q1 Operating Expenses
$19.91 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Precision BioSciences Inc is $24.50, about 221.1% above its May 4 closing price of $7.63

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)